miR‑212 regulated by HIF‑1α promotes the progression of pancreatic cancer

Yue,Hui; Liu,Lin; Song,Zhenguo

doi:10.3892/etm.2019.7213

miR‑212 regulated by HIF‑1α promotes the progression of pancreatic cancer

Authors:
- Hui Yue
- Lin Liu
- Zhenguo Song
View Affiliations

Affiliations: Key Laboratory of Cancer Prevention and Therapy, Department of Anesthesia, Cancer Institute, National Clinical Research Center for Cancer, Tianjin Medical University Hospital, Tianjin 300060, P.R. China
Published online on: January 29, 2019 https://doi.org/10.3892/etm.2019.7213
Pages: 2359-2365

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA‑212 (miR‑212) is dysregulated in numerous tissues and cancer types and serves a role in the progression of human cancer. However, the function and mechanism of miR‑212 in the development of pancreatic ductal adenocarcinoma (PDAC) remain unknown, particularly in a hypoxic microenvironment. In the present study, miR‑212 expression was observed to be significantly upregulated in PDAC tissues compared with normal tissues. Clinical data analysis indicated that miR‑212 was positively associated with a large tumor size, Tumor‑Node‑Metastasis stage, lymph node metastasis and vessel invasion, and influenced the overall survival time. Notably, there was a positive association between the expression of hypoxia‑inducible factor-1α (HIF‑1α) and miR‑212 in vivo and in vitro in hypoxic conditions. Mechanistically, HIF‑1α bound directly to a hypoxia response element in the miR‑212 promoter region and activated miR‑212 expression in PDAC cells. Collectively, these results demonstrated that HIF‑1α positively regulated miR‑212 expression and resulted in PDAC progression.

View Figures

View References

1	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
3	Adamska A, Domenichini A and Falasca M: Pancreatic ductal adenocarcinoma: Current and evolving therapies. Int J Mol Sci. 18:E13382017. View Article : Google Scholar : PubMed/NCBI
4	Lewis AR, Pihlak R and McNamara MG: The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma. Curr Probl Cancer. 42:26–39. 2018. View Article : Google Scholar : PubMed/NCBI
5	Uddin A and Chakraborty S: Role of miRNAs in lung cancer. J Cell Physiol. 20–Apr;2018.(Epub ahead of print). View Article : Google Scholar
6	Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
7	Wang Y, Bao W, Liu Y, Wang S, Xu S, Li X, Li Y and Wu S: miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1. Cell Death Dis. 9:4472018. View Article : Google Scholar : PubMed/NCBI
8	Idichi T, Seki N, Kurahara H, Fukuhisa H, Toda H, Shimonosono M, Okato A, Arai T, Kita Y, Mataki Y, et al: Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre-miR-148a on gene regulation. Cancer Sci. 109:2013–2026. 2018. View Article : Google Scholar : PubMed/NCBI
9	Liu B, Yang H, Taher L, Denz A, Grützmann R, Pilarsky C and Weber GF: Identification of prognostic biomarkers by combined mRNA and miRNA expression microarray analysis in pancreatic cancer. Transl Oncol. 11:700–714. 2018. View Article : Google Scholar : PubMed/NCBI
10	Xiong G, Huang H, Feng M, Yang G, Zheng S, You L, Zheng L, Hu Y, Zhang T and Zhao Y: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 37:762018. View Article : Google Scholar : PubMed/NCBI
11	Liu YA, Zhang Y, Zheng Z, Li K, Wu XH, Du QG, Ye X, Wang L and Zhu L: MicroRNA-216b reduces growth, migration and invasion of pancreatic ductal adenocarcinoma cells by directly targeting ρ-associated coiled-coil containing protein kinase 1. Oncol Lett. 15:6745–6751. 2018.PubMed/NCBI
12	Sun D, Wang X, Sui G, Chen S, Yu M and Zhang P: Downregulation of miR-374b-5p promotes chemotherapeutic resistance in pancreatic cancer by upregulating multiple anti-apoptotic proteins. Int J Oncol. 14–Mar;2018.(Epub ahead of print). View Article : Google Scholar
13	Xie F, Huang Q, Liu CH, Lin XS, Liu Z, Liu LL, Huang DW and Zhou HC: MiR-1271 negatively regulates AKT/MTOR signaling and promotes apoptosis via targeting PDK1 in pancreatic cancer. Eur Rev Med Pharmacol Sci. 22:678–686. 2018.PubMed/NCBI
14	Zhu W, Wang Y, Zhang D, Yu X and Leng X: MiR-7-5p functions as a tumor suppressor by targeting SOX18 in pancreatic ductal adenocarcinoma. Biochem Biophys Res Commun. 497:963–970. 2018. View Article : Google Scholar : PubMed/NCBI
15	Yuan Q, Zhang Y, Li J, Cao G and Yang W: High expression of microRNA-4295 contributes to cell proliferation and invasion of pancreatic ductal adenocarcinoma by the down-regulation of Glypican-5. Biochem Biophys Res Commun. 497:73–79. 2018. View Article : Google Scholar : PubMed/NCBI
16	Xia D, Li X, Niu Q, Liu X, Xu W, Ma C, Gu H, Liu Z, Shi L, Tian X, Chen X and Zhang Y: MicroRNA-185 suppresses pancreatic cell proliferation by targeting transcriptional coactivator with PDZ-binding motif in pancreatic cancer. Exp Ther Med. 15:657–666. 2018.PubMed/NCBI
17	Wanet A, Tacheny A, Arnould T and Renard P: miR-212/132 expression and functions: Within and beyond the neuronal compartment. Nucleic Acids Res. 40:4742–4753. 2012. View Article : Google Scholar : PubMed/NCBI
18	Xie M, Fu Z, Cao J, Liu Y, Wu J, Li Q and Chen Y: MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer. Biomed Pharmacother. 102:286–294. 2018. View Article : Google Scholar : PubMed/NCBI
19	Wu Z, Zhou L, Ding G and Cao L: Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma. Cancer Biomark. 18:35–39. 2017. View Article : Google Scholar : PubMed/NCBI
20	Jia P, Wei G, Zhou C, Gao Q, Wu Y, Sun X and Li X: Upregulation of MiR-212 inhibits migration and tumorigenicity and inactivates Wnt/β-catenin signaling in human hepatocellular carcinoma. Technol Cancer Res Treat. 17:15330346187652212018. View Article : Google Scholar : PubMed/NCBI
21	Hu B, Jin X and Wang J: MicroRNA-212 targets mitogen-activated protein kinase 1 to inhibit proliferation and invasion of prostate cancer cells. Oncol Res. 26:1093–1102. 2018. View Article : Google Scholar : PubMed/NCBI
22	Tang T, Huan L, Zhang S, Zhou H, Gu L, Chen X and Zhang L: MicroRNA-212 functions as a tumor-suppressor in human non-small cell lung cancer by targeting SOX4. Oncol Rep. 38:2243–2250. 2017. View Article : Google Scholar : PubMed/NCBI
23	Jiang C, Wang H, Zhou L, Jiang T, Xu Y and Xia L: MicroRNA-212 inhibits the metastasis of nasopharyngeal carcinoma by targeting SOX4. Oncol Rep. 38:82–88. 2017. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Zhao T, Jiang W, Wang X, Wang H, Zheng C, Li Y, Sun Y, Huang C, Han ZB, Yang S, et al: ESE3 inhibits pancreatic cancer metastasis by upregulating E-cadherin. Cancer Res. 77:874–885. 2017. View Article : Google Scholar : PubMed/NCBI
26	Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, Hostetter G, Shepard HM, Von Hoff DD and Han H: Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 21:3561–3568. 2015. View Article : Google Scholar : PubMed/NCBI
27	Liu H, Ma Q, Xu Q, Lei J, Li X, Wang Z and Wu E: Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer. Curr Pharm Des. 18:2395–2403. 2012. View Article : Google Scholar : PubMed/NCBI
28	Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura Ki, Hosokawa M and Asaka M: Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 61:6548–6554. 2001.PubMed/NCBI
29	Dengler VL, Galbraith M and Espinosa JM: Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol. 49:1–15. 2014. View Article : Google Scholar : PubMed/NCBI